Nephrology News
Metastatic Kidney Cancer Outcomes Improved With Combined Therapy
Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/